JP2018508528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508528A5 JP2018508528A5 JP2017546208A JP2017546208A JP2018508528A5 JP 2018508528 A5 JP2018508528 A5 JP 2018508528A5 JP 2017546208 A JP2017546208 A JP 2017546208A JP 2017546208 A JP2017546208 A JP 2017546208A JP 2018508528 A5 JP2018508528 A5 JP 2018508528A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- vegf
- diabetic
- fragment
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 82
- 239000012634 fragment Substances 0.000 claims description 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 15
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical group C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 13
- 208000002780 macular degeneration Diseases 0.000 claims description 11
- 201000004569 Blindness Diseases 0.000 claims description 10
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 10
- 206010038923 Retinopathy Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 10
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 10
- 230000004393 visual impairment Effects 0.000 claims description 9
- 208000017442 Retinal disease Diseases 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 230000008728 vascular permeability Effects 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 101710085003 Alpha-tubulin N-acetyltransferase Proteins 0.000 claims description 5
- 101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 claims description 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 5
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 5
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 206010029113 Neovascularisation Diseases 0.000 claims description 5
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 5
- 201000000582 Retinoblastoma Diseases 0.000 claims description 5
- 101710175714 Tyrosine aminotransferase Proteins 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 5
- 201000000159 corneal neovascularization Diseases 0.000 claims description 5
- 201000011190 diabetic macular edema Diseases 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 208000030533 eye disease Diseases 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical group 0.000 claims description 5
- 230000000302 ischemic effect Effects 0.000 claims description 5
- 238000013532 laser treatment Methods 0.000 claims description 5
- 108010043655 penetratin Proteins 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 5
- 108010011110 polyarginine Proteins 0.000 claims description 5
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 5
- 208000032253 retinal ischemia Diseases 0.000 claims description 5
- 108010062760 transportan Proteins 0.000 claims description 5
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 claims description 5
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims description 4
- 206010047571 Visual impairment Diseases 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000018769 loss of vision Diseases 0.000 claims description 4
- 231100000864 loss of vision Toxicity 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims description 4
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 208000029257 vision disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 11
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126968P | 2015-03-02 | 2015-03-02 | |
| US62/126,968 | 2015-03-02 | ||
| PCT/US2016/020443 WO2016141053A1 (en) | 2015-03-02 | 2016-03-02 | Peptides for inhibiting angiogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508528A JP2018508528A (ja) | 2018-03-29 |
| JP2018508528A5 true JP2018508528A5 (enExample) | 2019-04-11 |
| JP6896641B2 JP6896641B2 (ja) | 2021-06-30 |
Family
ID=55543089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546208A Active JP6896641B2 (ja) | 2015-03-02 | 2016-03-02 | 血管新生阻害ペプチド |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9675660B2 (enExample) |
| EP (1) | EP3265110B1 (enExample) |
| JP (1) | JP6896641B2 (enExample) |
| KR (1) | KR20170122762A (enExample) |
| CN (1) | CN107427549B (enExample) |
| AU (1) | AU2016226264B2 (enExample) |
| BR (1) | BR112017018665A2 (enExample) |
| CA (1) | CA2977389A1 (enExample) |
| DK (1) | DK3265110T3 (enExample) |
| ES (1) | ES2820710T3 (enExample) |
| IL (1) | IL253966B (enExample) |
| MX (1) | MX2017011170A (enExample) |
| PH (1) | PH12017501549B1 (enExample) |
| PL (1) | PL3265110T3 (enExample) |
| RU (1) | RU2708375C2 (enExample) |
| SG (1) | SG11201706799YA (enExample) |
| WO (1) | WO2016141053A1 (enExample) |
| ZA (1) | ZA201705934B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3849583B1 (en) * | 2018-09-11 | 2025-12-31 | Anbition S.r.l. | PEPTIDES FOR THE TREATMENT OF NEOVASCULAR EYE DISEASES |
| KR20210062649A (ko) * | 2018-09-11 | 2021-05-31 | 앤비션 에스.알.엘. | 펩티드 및 이의 의학적 용도 |
| CN113755634A (zh) * | 2021-10-12 | 2021-12-07 | 河南省农业科学院烟草研究所 | 一种鸢尾丝囊霉菌分子检测的特异引物及其检测方法 |
| CN115737677B (zh) * | 2022-07-25 | 2024-09-06 | 天津医科大学总医院 | 一种多肽修饰的金纳米颗粒在制备抑制糖尿病视网膜病变药物中的用途 |
| KR102587729B1 (ko) * | 2023-02-27 | 2023-10-12 | 주식회사 아이바이오코리아 | 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB9718609D0 (en) | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
| CN101014358A (zh) * | 2003-10-29 | 2007-08-08 | 约翰·霍普金斯大学 | 色素上皮所衍生因子的生物活性及使用方法 |
| US7368430B2 (en) | 2003-11-06 | 2008-05-06 | Research Development Foundation | Selective inhibitors of nuclear factor-κB activation and uses thereof |
| JP2008509157A (ja) * | 2004-08-06 | 2008-03-27 | ソフェリオン セラピューティクス，インコーポレイテッド | 抗血管新生ペプチドおよびその使用方法 |
| AU2008296733B2 (en) * | 2007-08-08 | 2013-07-11 | The Board Of Regents Of The University Of Texas System | VEGFR-1/NRP-1 targeting peptides |
| US20100222401A1 (en) * | 2008-04-16 | 2010-09-02 | University Of Utah Research Foundation | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
| FR2940032B1 (fr) | 2008-12-23 | 2013-08-09 | Seb Sa | Panier de cuisson d'aliments et systeme de cuisson correspondant |
| US20100190691A1 (en) | 2009-01-27 | 2010-07-29 | Trojan Technologies, Ltd | Delivery of nucleic acids using cell-penetrating peptides |
| EP2439514A1 (en) | 2010-10-01 | 2012-04-11 | Aqsens Oy | Method, apparatus, and system for examining optically a sample carried in a plurality of wells |
| ES2633343T3 (es) * | 2011-06-13 | 2017-09-20 | The Board Of Trustees Of The University Of Illionis | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
| CN102286101B (zh) * | 2011-08-08 | 2013-05-08 | 常州亚当生物技术有限公司 | 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用 |
-
2016
- 2016-03-02 CN CN201680012874.6A patent/CN107427549B/zh not_active Expired - Fee Related
- 2016-03-02 RU RU2017133101A patent/RU2708375C2/ru active
- 2016-03-02 PL PL16710568T patent/PL3265110T3/pl unknown
- 2016-03-02 AU AU2016226264A patent/AU2016226264B2/en active Active
- 2016-03-02 JP JP2017546208A patent/JP6896641B2/ja active Active
- 2016-03-02 BR BR112017018665-9A patent/BR112017018665A2/pt active Search and Examination
- 2016-03-02 MX MX2017011170A patent/MX2017011170A/es unknown
- 2016-03-02 DK DK16710568.3T patent/DK3265110T3/da active
- 2016-03-02 ES ES16710568T patent/ES2820710T3/es active Active
- 2016-03-02 EP EP16710568.3A patent/EP3265110B1/en active Active
- 2016-03-02 WO PCT/US2016/020443 patent/WO2016141053A1/en not_active Ceased
- 2016-03-02 US US15/058,938 patent/US9675660B2/en active Active
- 2016-03-02 KR KR1020177024830A patent/KR20170122762A/ko not_active Ceased
- 2016-03-02 SG SG11201706799YA patent/SG11201706799YA/en unknown
- 2016-03-02 CA CA2977389A patent/CA2977389A1/en active Pending
-
2017
- 2017-05-22 US US15/602,096 patent/US10064911B2/en active Active
- 2017-08-13 IL IL253966A patent/IL253966B/en active IP Right Grant
- 2017-08-29 PH PH12017501549A patent/PH12017501549B1/en unknown
- 2017-08-31 ZA ZA2017/05934A patent/ZA201705934B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508528A5 (enExample) | ||
| Casini et al. | The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases | |
| MX2013003890A (es) | Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas. | |
| MX2022001433A (es) | Tratamiento personalizado de enfermedades oftalmologicas. | |
| RU2014129316A (ru) | Способы ингибирования глазного ангиогенеза | |
| JP2017515811A5 (enExample) | ||
| EP4477233A3 (en) | A stable liquid formulation of fusion protein with igg fc domain | |
| JP2022183183A (ja) | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | |
| JP2021503914A5 (enExample) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| MX385629B (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. | |
| JP2017537985A5 (enExample) | ||
| RU2017133101A (ru) | Пептиды для ингибирования ангиогенеза | |
| JP2017532965A5 (enExample) | ||
| IL310376B1 (en) | Methods and compositions for treating angiogenic disorders using anti-VEGF factors | |
| JP2016521712A5 (enExample) | ||
| JP2019535651A5 (enExample) | ||
| WO2014062659A4 (en) | Methods of treating ocular diseases | |
| JP2016508372A5 (enExample) | ||
| PH12020551015A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| JP2018530574A5 (enExample) | ||
| CN103764830A (zh) | 含有irs-1抑制剂和vegf抑制剂的组合物 | |
| MX2021005077A (es) | Peptidos y composiciones farmaceuticas para tratar enfermedades oculares. | |
| Sawada et al. | Retinal vein occlusion | |
| CN111132664A (zh) | 治疗青光眼的Wnt5a的调节 |